Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Pidala, Joseph  [Clear All Filters]
Journal Article
Gandelman JS, Zic J, Dewan AK, Lee SJ, Flowers M, Cutler C, Pidala J, Chen H, Jagasia MH, Tkaczyk ER. The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2018.
Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf D, Pidala J, Flowers MED, Arora M, Jagasia M, Arai S, et al. Association of organ severity with mortality and recurrent malignancy in chronic graft-versus-host disease. Haematologica. 2014.
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, et al. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, Mogili K, Arslan S, Nishihori T, Nakamura R, et al. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide: CRS post haploidentical HCT with PTCy. Transplant Cell Ther. 2021.
Palmer J, Chai X, Martin PJ, Weisdorf D, Inamoto Y, Pidala J, Jagasia M, Pavletic S, Cutler C, Vogelsang G, et al. Failure-free Survival in a Prospective Cohort of Patients with Chronic Graft-Versus-Host Disease. Haematologica. 2015.
Chin K-K, Kim HT, Inyang E-A, Ho V, Koreth J, Romee R, Gooptu M, Shapiro R, Antin J, Soiffer R, et al. Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021.
Schutt SD, Fu J, Nguyen H, Bastian D, Heinrichs J, Wu Y, Liu C, McDonald DG, Pidala J, Yu X-Z. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice. PLoS One. 2015;10(9):e0137641.
Yang M-J, Yepez VV, Brandon KO, Reblin M, Pidala J, Jim HSL, Meyer JS, L Gore R, Khera N, Lau P, et al. A mindfulness-based stress management program for caregivers of allogeneic hematopoietic stem cell transplant (HCT) patients: Protocol for a randomized controlled trial. PLoS One. 2022;17(4):e0266316.
Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2014;7:CD010280.
Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, Flowers MED, Cutler C, Jagasia M, Gooley T, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther. 2021.
Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini PN, Boyiadzis M, Bredeson CN, et al. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival. Biol Blood Marrow Transplant. 2018.
Perez L, Fernandez H, Kharfan-Dabaja M, Khimani F, Betts B, Mishra A, Ayala E, Locke FL, Ochoa-Bayona L, Nieder M, et al. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Adv. 2021;5(13):2740-2750.
Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, et al. Pro-inflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes. Biol Blood Marrow Transplant. 2018.
Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, et al. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft vs. host disease. Haematologica. 2015.
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.
Koreth J, Pidala J, Perez WS, H Deeg J, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, et al. Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. J Clin Oncol. 2013.